bioMerieux (BMXMF)
(Delayed Data from OTC)
$122.50 USD
0.00 (0.00%)
Updated Sep 13, 2024 10:22 AM ET
3-Hold of 5 3
C Value B Growth F Momentum C VGM
Price, Consensus and EPS Surprise
BMXMF 122.50 0.00(0.00%)
Will BMXMF be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for BMXMF based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Other News for BMXMF
bioMérieux S.A. (BMXMF) Q2 2024 Earnings Call Transcript
BioMerieux SA (BMXMF) Q2 2024 Earnings Call Transcript Highlights: Strong Sales Growth and ...
Hologic Has A Lot Of Fine Qualities, But A Discount Valuation Isn't Among Them
bioMerieux initiated with bullish view at UBS, here's why
bioMerieux price target raised by EUR 3 at Morgan Stanley